---
figid: PMC9649345__gr2
pmcid: PMC9649345
image_filename: gr2.jpg
figure_link: /pmc/articles/PMC9649345/figure/f0010/
number: Fig. 2
figure_title: ''
caption: 'Angelica Yinzi attenuates DNCB-induced AD-like skin inflammation in C57BL/6
  mice. (A) Clinical features in mice treated with DNCB, AYZ, SDQP, CHT, and the control
  (B) Dermatitis scores on DNCB, AYZ, SDQP, CHT, and the control groups. (C) Total
  IgE levels in serum of mice treated with DNCB, AYZ, SDQP, CHT, and the control.
  (D) Representative photomicrographs of skin sections stained with H&E and TB (×200).
  In the TB staining panel, red arrows denote mast cells. Data are expressed as the
  mean ± SD. (n = 3). ##p < 0.01, vs. the control group. *p < 0.05 and **p < 0.01
  vs. the DNCB group.'
article_title: Angelica Yinzi alleviates 1-chloro-2,4-dinitrobenzene-induced atopic
  dermatitis by inhibiting activation of NLRP3 inflammasome and down-regulating the
  MAPKs/NF-kB signaling pathway.
citation: Wei Liu, et al. Saudi Pharm J. 2022 Oct;30(10):1426-1434.
year: '2022'

doi: 10.1016/j.jsps.2022.07.003
journal_title: 'Saudi Pharmaceutical Journal : SPJ'
journal_nlm_ta: Saudi Pharm J
publisher_name: Elsevier

keywords:
- Angelica Yinzi
- Atopic dermatitis
- MAPK
- NLRP3
- Inflammation

---
